Genentech DevSci DAC

Contact Information

DevSci DAC d-list
devsci-dac-d@gene.com

Request Access

This DAC controls 41 datasets

Dataset ID	Description	Technology	Samples
EGAD50000000139	Source data for Figure.2A heatmap showing the gene expression across samples.		1213
EGAD50000000140	Cell annotation for single T and NK cells of PBMC collected from 113 patients, including UMAP coordinates and annotation.		1213
EGAD50000000141	Raw count matrix for CITE-seq data of PBMC collected from 113 patients.		1213
EGAD50000000142	Raw count matrix for scRNA-seq data of PBMC collected from 113 patients.		1213
EGAD50000000143	Clinical data for IMvigor130 cohort of patients, including treatment, response, survial time, and tumor PDL1-IC staining score.		1213
EGAD50000000144	Cell annotation for single CD8 T cells of PBMC collected from 113 patients, including UMAP coordinates and annotation		1213
EGAD50000000145	Cell annotation for single cells of PBMC collected from 113 patients, including UMAP coordinates and annotation.		1213
EGAD50000000146	A list of ctDNA samples included in the dataset.		171
EGAD50000000147	ctDNA sample data (one sample per line) for BFAST Cohort D including sample-level summaries like tumor fraction (cTF).		171
EGAD50000000148	ctDNA mutation calls (one mutation per sample per line) for BFAST Cohort D including mutation-level data like coding change, allele frequency, etc.		171
EGAD50000000149	Clinical data for BFAST Cohort D, including time-to-event, tumor response, and baseline prognostics data.		231
EGAD50000000195	Relevant clinical data for IMpower133 (GO30081) including treatment arm, overall survival, progression-free survival, best overall response, PD-L1 IHC, molecular subtype, and baseline clinical features.		271
EGAD50000000196	This dataset contains log2(TPM + 1) for 271 tumor samples profiled by RNA-seq for the entire transcriptome for samples originating from IMpower133 (GO30081).		271
EGAD50000000273	311 genes		1
EGAD50000000312	RNAsequencing from 271 samples.	Illumina NovaSeq 6000	271
EGAD50000000366	Source data of clinical study data corresponding to figures reported in the paper titled: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells. PMID: 38418879 DOI: 10.1038/s41586-024-07121-9		293
EGAD50000000367	Source data of clinical study data corresponding to figures reported in the paper titled: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells. PMID: 38418879 DOI: 10.1038/s41586-024-07121-9		293
EGAD50000000368	Source data of clinical study data corresponding to figures reported in the paper titled: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells. PMID: 38418879 DOI: 10.1038/s41586-024-07121-9		293
EGAD50000000369	Matrix of counts from the serum peptide mass spec data from patients enrolled in the CITYSCAPE trial, and the sample annotation. Specifically, serum samples at C1D1, C2D1, C3D1, SCRN were collected from a total of 132 patients and subject to Mass Spec at Biognosys. The current study focused on patients who have samples at both C1D1 and C2D1 (n = 64 pairs). Associated metadata also included.		293
EGAD50000000370	Matrices of counts from single-cell RNA-seq data and single-cell CITE-seq data collected from 16 patients enrolled in GO30103 trial, and the cell level annotation. Specifically, PBMCs at C1D1, C1D15 (2 weeks after treatment), C2D1 (3 weeks after treatment) and C4D1 (9 weeks after treatment) were collected and subject to 10x Genomics protocol. Associated metadata also included.		293
EGAD50000000454	ctDNA biomarker and relevant clinical data for divarasib phase I GO42144 study, including tumor type, KRAS G12C mutation detectability in plasma at baseline, baseline SLD, sites of metastasis, lines of therapy, best response, confirmed best response, PFS, ctDNA tumor fraction and KRAS G12C VAF at baseline/C1D15/C3D1.		308
EGAD50000000483	Metadata associated with 16SV4 ribosomal RNA gene sequencing and Long read microbiome whole metagenome sequencing of pediatric GI samples.		20
EGAD50000000484	Sample sheet for aligning samples with patients.		20
EGAD50000000485	16SV4 ribosomal RNA gene sequencing data of GI samples and associated mixed community cultures collected from pediatric patients at risk for IBD.	Illumina MiSeq	11
EGAD50000000486	Long read microbiome whole metagenome sequencing of pediatric GI samples.	unspecified	9
EGAD50000000527	Raw 16SV4-sequence data from bronchial brushing DNA obtained from healthy volunteers prior to and four weeks after ICS treatment.	Illumina MiSeq	1
EGAD50000000528	Associated metadata for sequencing data.		63
EGAD50000000529	Barcodes associated with 16SV4 sequencing.		63
EGAD50000000530	Raw data of ctDNA profiling using the PredicineWES+ or PredicineBEACON assay in patients enrolled in divarasib phase I GO42144 study.	Illumina NovaSeq 6000	303
EGAD50000000568	Bulk RNAseq data for IMbrave151 (N = 96), including raw counts, transcript per million (TPM), and voom transformed values.		96
EGAD50000000569	Patient demographic characteristics, treatment, and survival data for IMbrave151 (N = 162), with one patient per line. Mapping file to map anonymized subject IDs to RNAseq IDs		96
EGAD50000000709	Binary calls for all available samples in 4 Atezo trials.		2803
EGAD50000000820	Read counts, per gene, aligning to exons. Alignment performed with GSNAP. 20 samples.		20
EGAD50000000826	RNA-seq data from ILC samples. This dataset includes raw, unnormalized counts per gene, per sample.		12
EGAD50000000827	Sample metadata for this experiment. Includes treatment and donor derivation information.		12
EGAD50000000828	RNA-seq data from ILC samples. This dataset includes counts normalized for sequencing depth and gene length.		12
EGAD50000000833	RNA-seq data from lumbar spinal cord blocks from 10 ALS samples and Controls. Raw fastq files are provided in this dataset.	Illumina NovaSeq 6000	20
EGAD50000000931	Tissue site for RNAsequencing data. Tissue site is associated with the clinical biomarker data and be linked to the biomarker data using the SAMPLE and PAT identifiers.	Illumina NovaSeq 6000	271
EGAD50000000932	T cell signatures from tumor RNAseq in CITYSCAPE with overall survival data. T cell signatures can be associated with the other clinical CITYSCAPE data .		293
EGAD50000001100	RNAseq TPM matrix (transcriptome profiling by high-thoughput sequencing) Matrix (30,727 features by 2,803 samples) of log2-transformed TPM counts from RNAseq data for the four IMvigor trials.		2803
EGAD50000001101	Clinical data include demographics (gender, race), specimen type (primary vs. metastatic), tract (upper vs. lower), liver metastasis status, PD-L1 IHC, tumor mutation burden, CD8 T cell infiltration status, neutrophil enrichment score, treatment arm, objective response rate, overall survival and progression free survival, and ctDNA status (IMvigor010 only) for 2803 patients across the four IMvigor trials.		2803